RNA, U1 small nuclear 94, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-94P profile across patient tissues and cancer cell-line models. RNU1-94P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RNU1-94P is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, RNU1-94P RNA expression shows 11,129 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight CHOL, LUSC, and KIRP as cancer lineages where RNU1-94P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-94P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-94P survival associations across molecular data types. RNU1-94P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-94P RNA expression–survival associations across cancer types. High RNU1-94P expression shows unfavorable associations in CHOL, DLBC, THCA, LIHC, LGG and KICH. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify CHOL as the clearest survival context for RNU1-94P RNA expression.
This table summarizes RNU1-94P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-94P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-94P shows lower tumor expression in LUSC, THCA and LUAD. The LUSC box plot shows higher RNU1-94P RNA expression in normal versus tumor tissue (log2 FC = −0.543, t-test p < 0.001).
This table shows molecular features associated with RNU1-94P in patient tissues and cancer cell lines. In patient samples, RNU1-94P shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
